Undefined
Ontology highlight
ABSTRACT:
PROVIDER: PRJEB55538 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Limosilactobacillus fermentum in industrial sugarcane ethanol bioprocess
| PRJEB52385 | ENA
Project description:controlled environment bacteria community composition
| PRJEB60062 | ENA
Project description:First draft genomes of Caprella mutica and Caprella linearis
| PRJEB57388 | ENA
Project description:Morphine and its pharmacological derivatives are the most prescribed analgesics for moderate to severe pain management. However, chronic use of morphine reduces pathogen clearance and induces bacterial translocation across the gut barrier. The enteric microbiome has been shown to play a critical role in the preservation of the mucosal barrier function and metabolic homeostasis. Here, we show for the first time, using bacterial 16s rDNA sequencing, that chronic morphine treatment significantly alters the gut microbial composition and induces preferential expansion of the gram-positive pathogenic and reduction of bile-deconjugating bacterial strains. A significant reduction in both primary and secondary bile acid levels was seen in the gut, but not in the liver with morphine treatment. Morphine induced microbial dysbiosis and gut barrier disruption was rescued by transplanting placebo-treated microbiota into morphine-treated animals, indicating that microbiome modulation could be exploited as a therapeutic strategy for patients using morphine for pain management. In this study, we establish a link between the two phenomena, namely gut barrier compromise and dysregulated bile acid metabolism. We show for the first time that morphine fosters significant gut microbial dysbiosis and disrupts cholesterol/bile acid metabolism. Changes in the gut microbial composition is strongly correlated to disruption in host inflammatory homeostasis13,14 and in many diseases (e.g. cancer/HIV infection), persistent inflammation is known to aid and promote the progression of the primary morbidity. We show here that chronic morphine, gut microbial dysbiosis, disruption of cholesterol/bile acid metabolism and gut inflammation; have a linear correlation. This opens up the prospect of devising minimally invasive adjunct treatment strategies involving microbiome and bile acid modulation and thus bringing down morphine-mediated inflammation in the host.
2016-06-01 | E-MTAB-3722 | biostudies-arrayexpress
Project description:Interventions: An explorative prospective multicenter cohort study in the Maastricht University Medical Centre+, Catharina Hospital and Zuyderland Medical Centre will be performed in 66 patients. Before, during, and after three cycles of systemic treatment with capecitabine or TAS-102, fecal samples and questionnaires (concerning compliance and chemotoxicity) will be collected. The response will be measured by CT/MRI using RECIST-criteria. Fecal microbiota composition will be analyzed with 16S rRNA next-generation sequencing. The absolute bacterial abundance will be assessed with quantitative polymerase chain reaction. Multivariate analysis will be used for statistical analysis.
Primary outcome(s): Microbiota composition before, during and after 3 cycles systemic treatment with capecitabine or TAS-102 related to respons & chemotoxicity
Study Design: N/A , unknown, Other
| 20955 | ecrin-mdr-crc
Project description:Here, we used bulk RNA-seq data derived from healthy colon organoids (un)exposed to ethanol. Through the use of external single cell RNA-seq data, we estimate changes in cell composition that are more pronounced in distal colon organoids following ethanol treatment. We extend this analysis by inferring cell-type-specific effects of ethanol treatment on colon organoids.
2020-12-14 | GSE150027 | GEO
Project description:Primary outcome(s): Differences in bacterial flora composition between colorectal cancer with ulcerative colitis and sporadic colorectal cancer
| 2654159 | ecrin-mdr-crc